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CollagenIdiopathic pulmonary ﬁbrosis (IPF) is a chronic progressive lung disease characterized by the development of
subpleural foci of myoﬁbroblasts that contribute to the exuberant ﬁbrosis. Recent studies revealed that pleural
mesothelial cells (PMCs) undergo epithelial–mesenchymal transition (EMT) and play a pivotal role in IPF. In an-
imalmodel, bleomycin induces pulmonaryﬁbrosis exhibiting subpleuralﬁbrosis similar towhat is seen inhuman
IPF. It is not known yet whether bleomycin induces EMT in PMCs. In the present study, PMCs were cultured and
treated with bleomycin. The protein levels of collagen-I, mesenchymal phenotypic markers (vimentin and α-
smooth muscle actin), and epithelial phenotypic markers (cytokeratin-8 and E-cadherin) were measured by
Western blot. PMC migration was evaluated using wound-healing assay of culture PMCs in vitro, and in vivo by
monitoring the localization of PMC marker, calretinin, in the lung sections of bleomycin-induced lung ﬁbrosis.
The results showed that bleomycin induced increases in collagen-I synthesis in PMC. Bleomycin induced signif-
icant increases inmesenchymal phenotypicmarkers and decreases in epithelial phenotypicmarkers in PMC, and
promoted PMCmigration in vitro and in vivo. Moreover, TGF-β1-Smad2/3 signaling pathway involved in the EMT
of PMCwas demonstrated. Taken together, our results indicate that bleomycin induces characteristic changes of
EMT in PMC and the latter contributes to subpleural ﬁbrosis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a chronic progressive lung dis-
ease of unknown cause that typically leads to respiratory failure and
death within 3–5 years of diagnosis (King et al., 2011). There are no ef-
fective pharmacological therapies yet for IPF. The pathological feature of
IPF includes ﬁbroproliferative foci, depositions of extracellular matrix
(ECM) including collagen and alveolar collapse. Interestingly, these his-
topathological alterations are predominantly located in subpleural areas
(Raghu et al., 2011). The cause for the subpleural distribution of ﬁbrotic
plague in IPF is not known. Recently, Mubarak et al. (2012) reported
that pleural mesothelial cells (PMCs) trafﬁcking into lung parenchyma
contributed to the subpleural ﬁbrotic foci in idiopathic pulmonaryC, pleuralmesothelial cell; EMT,
atrix; AEC, alveolar epithelial
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.
. This is an open access article underﬁbrosis. Nevertheless, it remains unclear how PMCs contribute to the
pathogenesis of subpleural pulmonary ﬁbrosis.
In IPF, myoﬁbroblasts are hallmark and prominent components
of lung tissue ﬁbrosis. They may be derived from several sources
of cells which undergo epithelial–mesenchymal transition (EMT).
Myoﬁbroblasts in pulmonary ﬁbrosis have been shown to arise from
resident pulmonary ﬁbroblasts or blood-borne ﬁbrocytes through
transdifferentiation (Hashimoto et al., 2004). Alveolar epithelial cells
(AECs) may undergo transdifferentiation and turn into myoﬁbroblasts
(Willis et al., 2005). PMCs can undergo EMT and play a pivotal role in
IPF (Decologne et al., 2010; Mubarak et al., 2012; Zolak et al., 2013).
PMCs undergoing EMT express distinct mesenchymal markers, lose ep-
ithelial markers and apicobasal polarity as well as intercellular junc-
tions. Changes in cell polarity and adhesion help epithelial cells
disrupt basementmembrane and penetrate into the ECM-rich compart-
ment (Lim and Thiery, 2012).
Bleomycin is widely used as an inducer in the animal models of pul-
monary ﬁbrosis. Very interestingly, lung ﬁbrosis induced by bleomycin
delivered to animals via different routes has different pattern of foci
distributions. For example, lung ﬁbrosis induced by intratrachealthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bronchus and is self-limiting (Chung et al., 2003; Moore and
Hogaboam, 2008). However, lung ﬁbrosis induced by multiple doses of
bleomycin by intraperitoneal injection exhibits a more chronic ﬁbrotic
state and subpleural ﬁbrotic distribution similar to what is seen in
human IPF (Mouratis and Aidinis, 2011). It has been reported that
PMCs are more susceptible to H2O2- and SiO2-induced oxidative stress
and damage than lung epithelial cells (Berg et al., 2013). These studies
suggest that PMCs should be more sensitive to the toxicity of bleomycin
than other lung cells. Nevertheless, it remains unknown whether
bleomycin can induceEMT in PMC. In the present study,we used cell cul-
ture and animal models and studied the effects of bleomycin on EMT in
PMC. We found, for the ﬁrst time, that bleomycin induces characteristic
changes of EMT in PMC and the latter contributes to subpleural ﬁbrosis.
Materials and methods
Materials and reagents. TGF-β1 was purchased from Sigma-Aldrich
Corp. (St. Louis, MO, USA). Enzyme-linked immunosorbent assay
(ELISA) kit for TGF-β1 and TGF-β1 receptor inhibitor (SB431542)
were obtained from R&D Systems (Minneapolis, MN, USA). Anti-
collagen-I antibody was obtained from Novus Biologicals (Littleton,
CO, USA). Antibodies against GAPDH and total-Smad2/3 (t-
Smad2/3) were obtained from Cell Signaling Technology (Danvers,
MA, USA). Antibodies against vimentin, α-smooth muscle actin (α-
SMA), cytokeratin-8, and E-cadherin were purchased from Epitomics
(Burlingame, CA, USA). Antibody against calretinin was purchased
from BD Transduction Laboratories (Lexington, KY, USA). Antibody
against phosphorylated-Smad2/3 (p-Smad2/3) was purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Bromodeoxyuridine
(BrdU) kit was obtained from Roche (Mannheim, Germany). Belomycin
was obtained from Tianjin Taihe Pharmaceutical Co., Ltd (Tianjin, China).
PMC culture and treatments. Human PMC line (MeT-5A) was purchased
from American Type Culture Collection (ATCC, Manassas, VA, USA). The
PMCs were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium (Hyclone, Logan, UT, USA) supplemented with 20% fetal calf
serum and 5% CO2, 95% air at 37 °C. The cells were 1:3 subcultured
when cells grow to conﬂuence, and culture medium was changed
every 2 days. The cells equilibrated in 2% serum medium overnight
were used for all experiments. PMCswere incubatedwith different con-
centrations of bleomycin (0.1–2 μg/ml) for 12–72 h.
Western blot analysis. EMT was monitored by measuring the protein
contents of collagen-I, vimentin, α-SMA, cytokeratin-8, and E-
cadherin, which are commonly used molecular markers for EMT.
The samples (10–20 μg of protein) of cell lysates were denatured and
electrophoresed on SDS–PAGE gel. Separated proteins were electro-
transferred to nitrocellulose membranes. The membranes were incu-
bated with 5% fat-free milk for 1 h, and then incubated with antibodies
against collagen-I, vimentin, α-SMA, cytokeratin-8, E-cadherin, or
GAPDH overnight at 4 °C, and then washed with 0.1% Tween-20,
20 mM Tris–HCl (pH 7.5) and 150 mM NaCl (TTBS) three times for
10 min. Secondary antibody IgG conjugated to alkaline phosphatase
was diluted in TTBS plus 5% nonfat milk and incubated with the mem-
branes at room temperature for 1 h. The membranes were washed
with TTBS and then developed with Supersignal West Pico (Pierce,
Rockford, IL, USA) for 3 min before exposure to ﬁlm (Kodak, Rochester,
NY, USA). Films were developed using Kodak Medical X-ray processor
102 (Kodak, Rochester, NY, USA) to visualize the reactive proteins
followed by densitometric quantiﬁcation using Image-Pro Plus software
(Media Cybernetics, Rockville, MD, USA).
Immunoﬂuorescence staining of PMC. To determine the intracellular
localization and changes of vimentin, α-SMA, cytokeratin-8, and E-
cadherin, PMCs were incubated with bleomycin (0.2 μg/ml) for72 h. Then the cells were stained using antibodies against vimentin,
α-SMA, cytokeratin-8, or E-cadherin overnight at 4 °C, and then
with tetramethyl rhodamin isothiocyanate (TRITC)-conjugated
goat anti-mouse, or goat anti-rabbit antibody for 30 min. The nuclei
were stained for DAPI for 10 minutes in dark. The ﬂuorescence-
labeled cells were examined using a ﬂuorescent microscope (Olym-
pus FV500, Olympus, Tokyo, Japan).
In vitro wound-healing assay of PMC migration. Conﬂuent monolayers
of PMCs in 6-well plates were scratched using the tip of a p-200 pi-
pette to create a uniform cell-free zone in each well. Cellular debris
was removed by washing with PBS. Wounded monolayers were
then incubated in the presence or absence of bleomycin. Microscopic
images were taken with a digital camera at 12 h, 24 h, and 48 h after
wounding. The recovered area was measured with a computer-
assisted image analysis system (Image-Pro Plus software) and
expressed as a percentage of the initial scratched area. At the same
time, morphologic changes in PMCs were observed by microscopy
when the cells were treated by bleomycin for 12 h, 24 h, and 48 h,
respectively.
Cell proliferation assay. Proliferation of PMCs was assayed using a kit
from Roche that monitors the incorporation of BrdU into newly syn-
thesized DNA. The BrdU was detected using anti-BrdU-peroxidase
conjugated in accordance with the manufacturer's instructions.
After reactions were stopped, the absorbance at 450 nm was mea-
sured using a Synergy 2 Multi-Mode microplate reader (Biotek In-
struments, Winooski, VT, USA).
Pulmonary ﬁbrosis animal model. Male C57BL/6 mice with ages of
12 weeks were purchased from Animal Center at Wuhan University.
The study protocol was approved by the Institutional Animal Care and
Use Committee of Tongji Medical College, Huazhong University of Sci-
ence and Technology. Pulmonary ﬁbrosis was induced by bleomycin
as previously described with minor modiﬁcation (Savani et al., 2000).
Brieﬂy, C57BL/6 mice (16–20 g; n = 5 per group) were housed under
standard conditions with free access to water and rodent laboratory
food. Bleomycin dissolved in saline solution (concentration, 5 mg/ml)
was administered by intraperitoneal injection at a dose of 50 mg/kg at
1, 5, 8, 11, and 15 days, respectively. In the control group, saline solution
without bleomycinwas administered by intraperitoneal injection at the
same time.Micewere euthanized at 40 days, and then lung tissueswere
taken for histological analysis.
Histological analysis. Mice lungs were removed and ﬁxed in 4% parafor-
maldehyde for 24 h. The ﬁxed lungs were then sliced midsagittally and
embedded in parafﬁn. The slides of 7 μm thickness were stained with
Masson staining for morphological analysis and evaluation of collagen
deposition. The slides were examined by using a microscope connected
with a digital camera and Image-Pro Plus software was used to analyze
the images.
Immunoﬂuorescence staining of lung tissue. The localization of
calretinin, a speciﬁc PMC marker, in lung sections of bleomycin-
induced lung ﬁbrosis was monitored as an indication of PMC migra-
tion in vivo. Frozen mouse lung sections were ﬁxed with 4% parafor-
maldehyde for 10 min at room temperature. The slides were
incubated with mouse anti-calretinin antibody (1:50 dilution) for
1 h and then with tetramethyl rhodamin isothiocyanate (TRITC)-
conjugated goat anti-mouse antibody for 30 min. The nuclei were
stained for DAPI for 10 minutes in dark. The slides were mounted
with anti-fade reagent and examined using a ﬂuorescent microscope
(Olympus FV500, Olympus, Tokyo, Japan). The p-Smad2/3 protein
was also stained using same method. The goat anti-p-Smad2/3 anti-
body dilution was 1: 50, and the second antibody was ﬂuorescein
isothiocyanate (FITC)-conjugated donkey anti-goat antibody.
Fig. 1. TGF-β1 induces EMT in human PMC line, MeT-5A cell. PMCs were incubated with TGF-β1 (5 ng/ml) for 24 h, after which intracellular protein contents of collagen-I, vimentin, α-
SMA, cytokeratin-8 and E-cadherinweremeasured byWestern blot as described in themethods. (A) Showing the image of immunoblots of collagen-I, vimentin,α-SMA, cytokeratin-8, E-
cadherin and GAPDH proteins from PMCs treated with or without TGF-β1. (B) Bar graphs depicting changes in relative density of collagen-I (n= 4), vimentin (n= 7), α-SMA (n= 4),
cytokeratin-8 (n= 6), and E-cadherin (n= 7) proteins. The density values of blots have been normalized to the control value. ⁎P b 0.05 versus control.
77L.-J. Chen et al. / Toxicology and Applied Pharmacology 283 (2015) 75–82ELISA for TGF-β1level in PMC. TGF-β1levels in PMCs were measured
using ELISA kit from R&D Systems (Minneapolis, MN, USA). The proce-
dures were performed according to manufacturer's instructions.
Statistical analysis. In each experiment, experimental and control
cells were matched for cell line, age, seeding density, number ofFig. 2. Effect of bleomycin on collagen-I synthesis in PMCs. PMCs were incubated with diffe
48 h, and 72 h, after which intracellular collagen-I protein contents were measured by We
lagen-I, and GAPDH proteins from PMCs treated with different concentration of bleomycin
n = 3, ⁎P b 0.05 versus control. (C) Showing a representative image of immunoblots of
bleomycin for 24 h, 48 h, and 72 h. (D) Bar graphs depicting changes in relative density o
blots have been normalized to the control value.passages, and number of days postconﬂuence to avoid variation
in tissue culture factors that can inﬂuence the result. Results are
shown as the mean ± SD for n experiments. Differences between
groups were analyzed using unpaired t tests or two-way analysis
of variance. P value less than 0.05 was considered to be statistically
signiﬁcant.rent concentration of bleomycin (0–2 μg/ml) for 24 h or 0.2 μg/ml bleomycin for 24 h,
stern blot as described in the methods. (A) Showing the image of immunoblots of col-
(0–2 μg/ml). (B) Bar graphs depicting changes in relative density of collagen-I protein.
collagen-I proteins from four separate experiments in PMCs treated with 0.2 μg/ml
f collagen-I protein. n = 4, ⁎P b 0.05 versus control. (B and D) The density values of
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TGF-β1 induces EMT in human PMC line, MeT-5A cell
MeT-5A cell is a human PMC line. To understand the properties of
MeT-5A cell and conﬁrm that EMT can be induced in MeT-5A cell,
TGF-β1 was used in cells culture. After treating MeT-5A cells with
TGF-β1 (5 ng/ml) for 24 h, we found that protein levels of collagen-I,
vimentin, and α-SMA in MeT-5A cells were increased (Fig. 1). On the
contrary, protein levels of cytokeratin-8 and E-cadherin in MeT-5A
cells were decreased (Fig. 1). These data suggested that human PMC
line, MeT-5A cell can be induced undergoing EMT process.
Bleomycin induces increases in collagen-I synthesis in PMCs
To investigate the effects of bleomycin on collagen-I synthesis in
PMCs, collagen-I protein in PMCs was measured by Western blot. We
found that incubation of PMCs with bleomycin (0.1–2 μg/ml) for 24 h
caused a dose-dependent increase in the protein level of collagen-I
(Figs. 2A and B). PMCs were then incubated with 0.2 μg/ml bleomycin
for 24 h, 48 h, and 72 h. We found that bleomycin-induced increase in
the protein level of collagen-I occurred as early as 24 h and continued
as long as 72 h (Figs. 2C and D).
Bleomycin induces increases in vimentin and α-SMA protein in PMCs
To conﬁrm the mesenchymal phenotypic transformation in
PMCs, cells were incubated with or without bleomycin (0.2 μg/ml)Fig. 3.Effect of bleomycin on vimentin andα-SMAprotein in PMCs. PMCswere incubatedwith b
protein contents were measured byWestern blot as described in the methods. Immunoﬂuores
(0.2 μg/ml) for 72 h. (A) is a representative image of immunoblots of vimentin protein. (B) is b
representative image of immunoﬂuorescence staining of vimentin. (D) is a representative imag
α-SMA protein according to D. (F) is a representative image of immunoﬂuorescence staining o
n= 4, ⁎P b 0.05 versus control.for 24–72 h. Mesenchymal phenotypic marker proteins, vimentin
and α-SMA, were measured by Western blot. As shown in Figs. 3A,
B, D, and E, incubation of PMCs with bleomycin for 24–72 h caused
signiﬁcant increases in protein levels of vimentin and α-SMA. To
show the expression of vimentin andα-SMA in situ, immunoﬂuores-
cence staining was done after cells were treated with bleomycin (0.2
μg/ml) for 72 h. As shown in Figs. 3C and F, expressions of vimentin
and α-SMA were much stronger in bleomycin treated cells than in
control cells. These results suggest that bleomycin induced PMC
transformation into ﬁbroblasts or myoﬁbroblasts.
Bleomycin induces decreases in cytokeratin-8 and E-cadherin protein in
PMCs
To further conﬁrm mesenchymal phenotypic transformation in-
duced by bleomycin in PMCs, epithelial phenotypic marker proteins,
cytokeratin-8 and E-cadherin, weremonitored byWestern blot and im-
munoﬂuorescence staining. As shown in Fig. 4, incubation of PMCswith
bleomycin resulted in decreases in protein levels of cytokeratin-8 and E-
cadherin, suggesting that bleomycin-treated PMCs lose the epithelial
phenotypic features.
Bleomycin increases cell migration of PMCs
Increased motility is one of the characteristics of cells undergo-
ing EMT. To determine whether bleomycin induces an increase in
PMC motility, the migration of PMCs was assessed using an
in vitro wound-healing assay on 6-well plates. As shown inleomycin (0.2 μg/ml) for 24h, 48h, and 72h, afterwhich intracellular vimentin andα-SMA
cence staining of vimentin and α-SMA in situwas done after cells treated with bleomycin
ar graphs depicting changes in relative density of vimentin protein according to A. (C) is a
e of immunoblots ofα-SMA protein. (E) Bar graphs depicting changes in relative density of
f α-SMA. (B and E) The density values of blots have been normalized to the control value.
Fig. 4.Effect of bleomycin on cytokeratin-8 and E-cadherinprotein in PMCs. PMCswere incubatedwith bleomycin (0.2 μg/ml) for 24 h, 48 h, and 72h, afterwhich intracellular cytokeratin-
8 and E-cadherin protein contents weremeasured byWestern blot. Immunoﬂuorescence staining of cytokeratin-8 and E-cadherin in situwas done after cells treatedwith bleomycin (0.2
μg/ml) for 72 h. (A) is a representative image of immunoblots of cytokeratin-8 protein. (B) is bar graph depicting changes in relative density of cytokeratin-8 according to A. (C) is a rep-
resentative image of immunoﬂuorescence staining of cytokeratin-8. (D) is a representative image of immunoblots of E-cadherin protein. (E) is bar graph depicting changes in relative den-
sity of E-cadherin according to D. (F) is a representative image of immunoﬂuorescence staining of E-cadherin. (B, E) The density values of blots have been normalized to the control value.
n= 4, ⁎P b 0.05 versus control.
79L.-J. Chen et al. / Toxicology and Applied Pharmacology 283 (2015) 75–82Figs. 5A and B, incubation of PMCs with bleomycin (0.2 μg/ml)
caused an increase in PMC migration. Recovered area was about
40% in bleomycin treated group compared with 25% in control
group at 12 h. It was about 70% in bleomycin treated group com-
pared with 40% in control group at 24 h. The space of wound was
completely ﬁlled with migrating PMCs after incubation with
bleomycin for 48 h. To distinguish cell migration from cell prolifer-
ation, cell proliferation was detected by using a BrdU incorporation
assay. Bleomycin did not change cell proliferation in PMCs at 12 h,
and 48 h, slightly induced cell proliferation at 24 h (Fig. 5D). These
data suggest that bleomycin induces an increase in PMC migration
rather than cell proliferation.Bleomycin causes changes in morphology of PMCs into ﬁbroblasts-like
In the experiments of in vitrowound-healing assay, morphologic
changes of PMCs were documented by usingmicroscope at the same
time. As shown in Fig. 5C, PMCs cultured in the absence of
bleomycin (control) showed epithelial morphology of typical po-
lygonal and cobblestone monolayer. PMCs treated with bleomycin
for 12–48 h showed remarkable phenotypic changes (Figs. 5C-f, g,
and h). Bleomycin-treated PMCs showed elongated and spindle
shaped morphology of ﬁbroblasts-like feature, also suggesting that
bleomycin induced mesenchymal phenotypic transformation in
PMCs.PMCs migrate into the ﬁbrotic lung parenchyma in bleomycin-induced
pulmonary ﬁbrosis model
We further evaluated bleomycin-induced PMC migration in vivo by
monitoring location of calretinin, a marker of mesothelial cells in
mouse lungs in a pulmonary ﬁbrosismodel. Forty days afterﬁrst admin-
istration of bleomycin, lung sections from control mice andmice receiv-
ing bleomycin were subjected to immunoﬂuorescence staining for
calretinin. As shown in Figs. 6B, C, and D, there were abundant collagen
ﬁbers deposited in the ﬁbrotic plague in subpleural lung tissue (Masson
staining, blue color). In the control mice, as there is no adhesion of pleu-
ra with lung parenchyma, so when the lung was taken from the thorax,
the pleural membrane was separated from the lung surface. Thus, there
was no pleura in the normal lung tissue section, calretinin staining was
negative (Fig. 6E). In ﬁbrotic lungs, calretinin protein was expressed in
the pleura and parenchyma (Figs. 6F, G, and H), indicating that PMCs
migrate into lung parenchyma in bleomycin-induced pulmonary
ﬁbrosis.TGF-β1-Smad2/3 signaling pathway is involved in the EMT of PMC
To knowwhether TGF-β1-Smad2/3 signaling pathway is involved in
the EMTof PMC, we detected TGF-β1 in PMCs by using ELISA kit, and in-
vestigated p-Smad2/3 by using Western blot. Furthermore, we did im-
munoﬂuorescence staining of p-Smad2/3 in the mouse lung sections.
Fig. 5. Effect of bleomycin on in vitro PMCmigration. PMCs were subcultured in the 6-well plate. Conﬂuentmonolayers of PMCs were scratched with the tip of a p-200 pipette to create a
uniform cell-free zone in eachwell.Woundedmonolayerswere then incubated in the presence or absence of bleomycin (0.2 μg/ml). Microscopy pictures were takenwith a digital camera
at different time points (12 h, 24 h, and 48 h) after scratching. The recovered area was measured with a computer-assisted image analysis system and expressed as a percentage of the
initial scratched area. (A) is representative image of PMC migration from three separate experiments. (B) is line graph depicting changes of recovered area in percentage of the initial
scratched area. n= 3, ⁎P b 0.05 versus control. (C) is one part of image from A to showmorphologic changes of PMCs. (D) is bar graph depicting changes of cell proliferation. The values
have been normalized to the control value. n= 20, ⁎P b 0.05 versus control.
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Smad2/3 in PMCs (Figs. 7A and B). In the animal model, the protein
levels of p-Smad2/3 were also dramatically increased in the mouse
lungs of bleomycin-induced pulmonary ﬁbrosis (Fig. 7C, green color is
p-Smad2/3 staining). Then we used TGF-β1 receptor inhibitor,
SB431542 to block the TGF-β1-Smad2/3 pathway, and investigated
changes of EMT marker proteins in PMCs. As shown in Figs. 7D and E,
SB431542 prevented increases of vimentin and decreases of
cytokeratin-8 which induced by bleomycin. Taken together, these data
suggested that the TGF-β1-Smad2/3 signaling pathway is involved in
EMT induced by bleomycin in PMC.
Discussion
According to the description about MeT-5A cell line from ATCC, we
know that the cells were isolated from pleural ﬂuids obtained fromnon-cancerous individuals. The cells were transfected with p-RSV-T
plasmid (an SV40 ori-construct containing the SV40 early region and
the Rous sarcoma virus long terminal repeat) and cloned. Previous pub-
lications have indicated that TGF-β1 induces EMT in PMC (Nasreen
et al., 2009). In order to conﬁrm that EMT can be induced in MeT-5A
cell, TGF-β1 was used to treat the cells. Not surprisingly, TGF-β1 in-
duced increases in collagen-I, vimentin, andα-SMA protein expression,
and decreases in cytokeratin-8 and E-cadherin protein expression in
MeT-5A cells. Thus, we used the MeT-5A cell line as a PMC model for
EMT study.
In the present study, we conﬁrmed for the ﬁrst time that bleomycin
induces EMT in PMC, and TGF-β-Smad2/3 signaling pathway is involved
in the underling mechanism. We found that bleomycin induced dose-
and time-dependent increases in collagen-I synthesis in PMCs.
Bleomycin-treated PMCs have signiﬁcantly higher protein levels ofmes-
enchymal phenotypicmarkers, vimentin andα-SMA, and lower protein
Fig. 6. PMC migration in the ﬁbrotic lungs from bleomycin-induced pulmonary ﬁbrosis
model. Pulmonary ﬁbrosis was induced by multiple intraperitoneal injections of
bleomycin in mice. At day 40 after ﬁrst injection, mice were euthanized and lung tissues
were taken. The lung sections were stained with Masson staining for morphological anal-
ysis. Calretinin was also stained for immunoﬂuorescence. (A) is representative image of
Masson staining of lung sections from control group. (B, C, and D) are representative im-
ages of Masson staining of lung sections from bleomycin-induced pulmonary ﬁbrosis
group. (E) is representative image of calretinin immunoﬂuorescence staining of lung sec-
tions from control group. (F, G, and H) are representative images of calretinin immunoﬂu-
orescence staining of lung sections from bleomycin-induced pulmonary ﬁbrosis group.
(IF: immunoﬂuorescence; A–D: blue color is collagen; E–H: red color is calretinin, blue
color is DAPI. n= 5).
81L.-J. Chen et al. / Toxicology and Applied Pharmacology 283 (2015) 75–82level of epithelial phenotypic markers, cytokeratin-8 and E-
cadherin. Moreover, bleomycin promoted PMC migration in vitro
and in vivo. Bleomycin-treated PMCs became elongated and spindle
shaped, showing characteristic morphology of ﬁbroblasts or
myoﬁbroblasts. Lastly, we got evidences indicating that bleomycin
induces characteristic changes of EMT through TGF-β1-Smad2/3
pathway in PMCs.
Bleomycin is a chemotherapeutic agent used in the treatment of a
variety of tumors including lymphoma, squamous cell carcinoma
and testicular carcinoma. Although bleomycin has been claimed to
have minimal immunosuppressive activity and low hematopoietictoxicity, chemotherapy using bleomycin is often complicated by in-
terstitial pulmonary ﬁbrosis (Kawai and Akaza, 2003; Kim et al.,
2010). Thus, bleomycin has been widely used in making pulmonary
ﬁbrosis animal models (Lee et al., 2014). Repetitive administrations
of bleomycin by intraperitoneal or intravenous injection induce
pleural and subpleural ﬁbrosis, which is similar to what is seen in
human IPF (Mouratis and Aidinis, 2011). Thus, researchers consider
that PMCs are more sensitive to the toxicity of bleomycin or
proﬁbrotic growth factors than other lung cells (Berg et al., 2013),
which should be the mechanism of pleural and subpleural ﬁbrosis.
Vimentin is a major intermediate ﬁlament protein in mesenchymal
cells (Eriksson et al., 2009). α-SMA is a marker of mesenchymal
cells and mainly expressed in myoﬁbroblasts (Kage and Borok,
2012). E-cadherin is a cellular junctional protein and maintains the
epithelial integrity. Cytokeratin is a cytoskeletal intermediate ﬁla-
ment protein, and there are about 20 subtypes expressed in various
types of human epithelial cells (Yi and Ku, 2013). Both cytokeratin-
8 and E-cadherin are epithelial phenotypic marker proteins in
PMCs (Nasreen et al., 2009; Kim et al., 2011). In the current study,
we found that bleomycin-treated PMCs progressively lose the ex-
pression of cytokeratin-8 and E-cadherin and gradually acquire in-
creased expression of vimentin and α-SMA. This is direct evidence
indicating that bleomycin induces EMT in PMCs.
After losing of the cellular junctions and changes in the cytoskel-
eton, PMCs acquire increased ability for migration. Our ﬁnding
shows that bleomycin-treated PMCs migrate much faster in an
in vitro wound repair study. Calretinin is a marker of mesothelial
cells (Kachali et al., 2006). After demonstrating that calretinin is
stably expressed in bleomycin-treated PMCs (Supplemental Mate-
rials, Fig. S1), we detected the localization of calretinin in lung tis-
sue, and found that calretinin is mainly located in the subpleural
area of lung parenchyma in ﬁbrotic lungs of mice receiving repeti-
tive intraperitoneal injection of bleomycin. These data suggest
that PMCs migrate into subpleural area of lung parenchyma. More-
over, our results indicate that bleomycin induced increases in
collagen-I protein in PMCs. Increasing ability of collagen-I synthesis
in PMC is not only a sign of EMT, but also a sign of remodeling disor-
der. Thus, PMC produces more collagen-I and then contributes to
the deposition of extracellular matrix for subpleural ﬁbrosis when
the cell is undergoing EMT.
The mechanism for bleomycin-induced EMT of PMCs is not known.
TGF-β1-Smad2/3 signaling pathway is considered as a typical pathway
in EMT (Chapman, 2011). We found that bleomycin induced increases
in TGF-β1 levels and p-Smad2/3 in PMCs, and TGF-β1 receptor inhibitor
prevented EMT in PMCs. We also found that p-Smad2/3 level is much
higher in lungs of bleomycin-treated mice. These results indicate that
bleomycin induces characteristic changes of EMT through TGF-β1-
Smad2/3 pathway in PMCs, and the latter contributes to subpleural
ﬁbrosis.
In summary, bleomycin induces an increase in collagen-I synthe-
sis in PMCs. Bleomycin-treated PMCs acquire mesenchymal pheno-
typic markers and lose epithelial phenotypic markers and exhibit
an increased motility. We conclude that bleomycin induces EMT in
PMCs, which contribute to subpleural ﬁbrosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2015.01.004.
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